FunderNation • Dendropharm
Equity crowdfunding
Dendropharm
Nanotechnology for Potent Painkillers Without Addiction or Sedation
Key project data
Target amount
1.0 MEUR
Valuations
10.0 MEUR
Potential Returns
8,16 x
Would AI invest?
51/100
1
100
AI-Generated Overview
AI project overview
Condensed summary based on project data
<h1><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">DendroPharm GmbH — Crowdfunding Investor Memo</span></span></h1> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><em>Nanotechnology for potent painkillers without addiction or sedation.</em></span></span></p> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong>Sector: </strong>Pharma / nanotech drug delivery (deeptech, regulated) · <strong>Stage: </strong>Pre-clinical (Phase I planned Q3 2026) · <strong>HQ: </strong>Berlin, Germany · <strong>Raise: </strong>EUR 100k threshold – EUR 1.0m maximum</span></span></p> <table cellspacing="0" class="Table" style="border-collapse:collapse; border:none; width:6.5in"> <tbody> <tr> <td style="background-color:#faece7; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:200px"> <p> </p> </td> <td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:424px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Why this score:</span></strong></span></span></p> </td> </tr> <tr> <td style="background-color:#faece7; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:200px"> <p style="text-align:center"><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">AI SCORE</span></strong></span></span></p> </td> <td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:424px"> <ul> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">The headline 48–52% annual return is a company projection on a profit-/exit-linked loan, not a fixed coupon; the VIB states neither principal nor interest is assured under negative development.</span></span></span></li> </ul> </td> </tr> <tr> <td style="background-color:#faece7; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:200px"> <p style="text-align:center"><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="font-size:28.0pt"><span style="color:black">51 / 100</span></span></strong></span></span></p> </td> <td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:424px"> <ul> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">The investment is a deeply subordinated loan with a pre-insolvency enforcement bar: payments can be lawfully blocked before insolvency and the lender is paid only after all other creditors.</span></span></span></li> </ul> </td> </tr> <tr> <td style="background-color:#faece7; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:200px"> <p style="text-align:center"><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="font-family:"Segoe UI Emoji",sans-serif"><span style="color:black">⚠️</span></span><span style="color:black"> Caution</span></strong></span></span></p> </td> <td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:424px"> <ul> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">The asset is pre-clinical (Phase I planned Q3 2026) and the return path depends on out-licensing modelled for 2028–2031 plus a not-yet-secured EUR 3–6m VC round for Phase II.</span></span></span></li> </ul> </td> </tr> <tr> <td style="background-color:#faece7; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:200px"> <p style="text-align:center"> </p> </td> <td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:424px"> <ul> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">The two financial scenarios disagree on 2025 ‘actuals’ and on out-licensing magnitude/timing (EUR 45m vs 35m in 2030).</span></span></span></li> </ul> </td> </tr> <tr> <td style="background-color:#faece7; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:200px"> <p style="text-align:center"> </p> </td> <td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:424px"> <ul> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Credible foundations: ISO 9001 (2015), GMP (2022, LaGeSo), manufacturing-authorisation inspection completed Sept 2025, BMBF/Pro FIT grants, and a 12-person specialist team.</span></span></span></li> </ul> </td> </tr> </tbody> </table> <p> </p> <table cellspacing="0" class="Table" style="border-collapse:collapse; border:none; width:6.5in"> <tbody> <tr> <td style="background-color:#e6f1fb; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:624px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">ℹ️ <strong>This is not investment advice.</strong> The purpose of this overview is to help potential investors preselect crowdfunding projects quickly. Before investing, the final selected project should be reviewed in detail based on the information provided by the company on the respective crowdfunding platform, and you may want to seek independent professional advice.</span></span></span></p> </td> </tr> </tbody> </table> <h2><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">🎯 Key goal</span></span></h2> <table cellspacing="0" class="Table" style="border-collapse:collapse; border:none; width:6.5in"> <thead> <tr> <td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:113px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Target return</span></strong></span></span></p> </td> <td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:113px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Time horizon</span></strong></span></span></p> </td> <td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:224px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Target basis</span></strong></span></span></p> </td> <td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:173px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">AI view on reaching this goal</span></strong></span></span></p> </td> </tr> </thead> <tbody> <tr> <td style="background-color:white; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:113px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">🎯 6.80–8.16x</span></strong></span></span></p> </td> <td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:113px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">⏱ ~5 yrs (to 30.04.2031)</span></strong></span></span></p> </td> <td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:224px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Company-provided</span></strong><span style="color:black"> — the company states 48% (base) to 52% (target) IRR per year over a 5-year period, i.e. 6.80x–8.16x.</span></span></span></p> </td> <td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:173px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Plausible only on a successful out-licensing exit; under the VIB’s neutral/negative cases the multiple is not achieved and capital loss is possible.</span></span></span></p> </td> </tr> </tbody> </table> <h2><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">📈 Path to target return</span></span></h2> <table cellspacing="0" class="Table" style="border-collapse:collapse; border:none; width:6.5in"> <tbody> <tr> <td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:173px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Company methodology</span></strong></span></span></p> </td> <td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:451px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Returns are success-based, not contractual. During the term the investor earns an annual ‘success interest’ equal to their participation quota × the company’s prior-year net profit; at the end of term a ‘bonus interest’ based on company value (or, absent a recent financing round, 100% of last-year revenue); and, on a sale of >50% of shares/assets, an ‘exit interest’ (a pro-rata share of net proceeds) plus principal back. The 48–52% IRR / 6.8–8.16x figures are the company’s modelled outputs assuming positive growth and a successful out-licensing exit.</span></span></span></p> </td> </tr> <tr> <td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:173px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Comparable exits cited</span></strong></span></span></p> </td> <td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:451px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Not disclosed in provided materials. The company estimates lifetime out-licensing revenue of EUR 1.2–1.8bn over the patent term (company-stated, unverified), with 20–30% within the first four years.</span></span></span></p> </td> </tr> <tr> <td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:173px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Milestones expected</span></strong></span></span></p> </td> <td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:451px"> <ul> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Phase I start — Q3 2026</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Phase II start (patient efficacy) — Q3 2027 (requires a EUR 3–6m VC round)</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Depot-formulation Phase II — 2029</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Out-licensing — 2028–2031</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Veterinary cat-ointment approval — 2026</span></span></span></li> </ul> </td> </tr> </tbody> </table> <h2><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">🏢 Company description</span></span></h2> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">DendroPharm GmbH (Berlin; HRB 151543 B) is a pharmaceutical R&D and contract-manufacturing company developing a nano-carrier platform branded “NanoPain™” / “NanoOpiate.” The company reports the carrier is too large to cross the blood-brain barrier, so it delivers an already-approved opioid to inflamed or post-operative tissue rather than the brain, aiming to relieve pain without the addiction and respiratory-depression risks of conventional opioids; the intravenous candidate is “DENA-19.” Founded in 2013 as a spin-off from Freie Universität Berlin (the project team reports it “took over the project in 2017”), it is led by founder/CEO Dr. Sam Dylan Moré, who holds 56.39% of the equity. The company reports a 12-person specialist team across more than 650 sqm including 300 sqm of cleanrooms and 5 analytical laboratories, ISO 9001 certification since 2015, GMP certification in 2022 (LaGeSo), and a completed manufacturing-authorisation inspection in September 2025. Current revenue is project/CDMO-based (the company reports ~EUR 600,000 of 2026 customer inquiries) alongside a veterinary cat-ointment out-licensed in 2021 and expected to be approved in 2026. This round — a profit-participating subordinated loan with an EUR 100,000 threshold and EUR 1,000,000 maximum — is earmarked to fund the first human clinical trial (Phase I) and to advance out-licensing of the Nano-Pain technology. The company separately plans a EUR 3–6m venture-capital equity round to enable Phase II in 2027.</span></span></p> <h2><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">💶 Valuation</span></span></h2> <table cellspacing="0" class="Table" style="border-collapse:collapse; border:none; width:6.5in"> <tbody> <tr> <td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:200px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Pre-money valuation</span></strong></span></span></p> </td> <td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:424px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">EUR 10.0m (set by the issuer, before the campaign).</span></span></span></p> </td> </tr> <tr> <td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:200px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Post-money valuation</span></strong></span></span></p> </td> <td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:424px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">EUR 11.0m implied at the EUR 1.0m maximum raise (derived).</span></span></span></p> </td> </tr> <tr> <td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:200px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Instrument</span></strong></span></span></p> </td> <td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:424px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Partiarisches Nachrangdarlehen — a profit-participating subordinated loan. This is NOT equity: the investor receives no shares and no ownership.</span></span></span></p> </td> </tr> <tr> <td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:200px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">How the valuation was set</span></strong></span></span></p> </td> <td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:424px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Methodology not disclosed in provided materials — the EUR 10m figure is stated as issuer-determined, with no DCF or comparables basis provided.</span></span></span></p> </td> </tr> <tr> <td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:200px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">External benchmarks</span></strong></span></span></p> </td> <td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:424px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Insufficient comparables for this sector and stage; no third-party valuation was found in public sources. The asset is pre-Phase-I, so the figure is forward-looking on out-licensing potential.</span></span></span></p> </td> </tr> <tr> <td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:200px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Notable terms</span></strong></span></span></p> </td> <td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:424px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">A ~10% valuation bonus applies to investors within 31 days of public presentation (EUR 100 → 0.001000% participation quota vs 0.000909% standard). Issuer-borne costs total 15% of amounts raised (FunderNation 6%, pooling ~6%, marketing up to 3%).</span></span></span></p> </td> </tr> </tbody> </table> <h2><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">📜 Instrument & investor terms</span></span></h2> <h3><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">What you own</span></span></h3> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">You own a profit-participating subordinated loan (German: partiarisches Nachrangdarlehen), not shares. There is no share class because this is debt, not equity — you become a lender to the company, not a co-owner, and you do not appear on the company’s cap table. The loan is made directly to DendroPharm (not through a nominee or SPV), but a separate pooling agreement via FunderNation Support UG provides a collective coordination procedure (for example, to negotiate a whole-loan buy-out or a sale of the company on behalf of all lenders). You have no voting rights and no say in company decisions, including the decision to sell the company; under this instrument type, lenders carry no membership, voting, or control rights. Exit decisions are therefore made by the shareholders (the CEO alone holds 56.39%), with lenders able only to coordinate collectively through the pooling mechanism.</span></span></p> <h3><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">Dilution and future rounds</span></span></h3> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">The company has stated it intends to raise a EUR 3–6m venture-capital equity round to fund Phase II in 2027, and its financial plan also models further equity-type inflows in 2026–2028. Because you hold debt rather than equity, you have no shareholding to be diluted in the ordinary sense, and crowdfund lenders here have no anti-dilution protection. However, two debt-specific mechanics matter, and the worked example below uses them.</span></span></p> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong>Worked example (standard mechanics for this instrument). </strong>If you invest EUR 1,000 today, your participation quota is fixed at subscription against the EUR 10m pre-money valuation plus the total amount raised. At the EUR 1.0m maximum raise (EUR 11m reference), EUR 1,000 buys roughly a 0.00909% quota (or about 0.01% with the ~10% early-bird bonus). This quota does not shrink when a later EUR 3–6m equity round is added, because it was set against a fixed denominator — but that quota only ever entitles you to that fraction of the company’s prior-year net profit as annual success interest. The more consequential mechanic is the end-of-term valuation reference: your bonus interest is calculated from the company value set at the most recent financing round within 12 months before the loan ends, or — if no such round occurred — from just 100% of the last year’s revenue. So if a strong VC round near term-end sets a high company value, your bonus interest reference is higher; if there is no recent round and revenue is modest, the reference can be far lower than the EUR 10m headline. Your downside is not gradual dilution but the risk that profit, company value, or an exit simply do not materialise, in which case you receive only principal back (in 12 monthly instalments from May 2031) or, in a bad scenario, less than principal or nothing.</span></span></p> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">No ESOP or option-pool plans are disclosed in the provided materials, so their dilutive effect cannot be assessed. You have no pre-emption rights — as a lender, you have no contractual right to participate in future equity rounds to defend a percentage, because you do not hold a percentage of equity to begin with.</span></span></p> <h3><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">Exit and liquidation mechanics</span></span></h3> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">The payout order is explicitly unfavourable to you. This loan carries qualified subordination plus a pre-insolvency enforcement bar: in a liquidation or insolvency, your claim ranks AFTER all non-subordinated creditors and even after the subordinated claims listed in §39(1) of the German Insolvency Code, so you are satisfied only after everyone else has been paid in full. There is no liquidation preference in your favour (this is not preferred equity); there is no stated multiple. In a sale or wind-down below or near the company’s value, lenders in this position commonly receive little or nothing.</span></span></p> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">No drag-along threshold (the percentage of holders who can force everyone to sell on the same terms) and no tag-along right (the right to join a sale on the same terms as a selling shareholder) are disclosed for crowdfund lenders — these are equity concepts and you hold debt. The nearest equivalent is the exit-interest clause: if more than 50% of shares or key assets are sold during the term, you receive principal back plus a pro-rata share of net sale proceeds by quota, and the loan then ends.</span></span></p> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">Treat this investment as illiquid for its full term. There is no ordinary right to terminate early for either side; the loan is locked until 30 April 2031 (roughly five years), with extraordinary termination only for good cause. There is no functioning secondary market — resale is legally possible but, per the platform’s own risk notice, “difficult or even impossible” in practice because no comparable trading venue exists.</span></span></p> <h3><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">Key risks specific to this instrument</span></span></h3> <ul> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">Pre-insolvency enforcement bar — interest and repayment can be lawfully reduced, delayed, or stopped even before any insolvency if payment would trigger or coincide with an insolvency ground, persisting as long as the crisis lasts, up to total loss.</span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">Deepest-rank subordination — you are paid only after all other creditors, including the §39(1) InsO subordinated ones; in a low-value exit or wind-down you may receive little or nothing.</span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">No fixed return — there is no guaranteed coupon; the entire upside depends on prior-year net profit, end-of-term company value/revenue, or an exit, none of which is assured (the VIB’s neutral case yields no success interest).</span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">No voting rights — you cannot influence company decisions, including whether and when to sell; the CEO alone controls 56.39% of the equity.</span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">Illiquidity to 30.04.2031 — no ordinary early exit and no functioning secondary market, so funds are committed for the full term.</span></span></li> </ul> <h3><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">Items not disclosed</span></span></h3> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">Absence of disclosure means you cannot assess these before investing:</span></span></p> <ul> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">Valuation methodology supporting the EUR 10m pre-money.</span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">Any cap, floor, or detailed numeric example for the bonus interest and exit interest beyond the quota formula.</span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">Founder vesting schedule and leaver provisions.</span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">ESOP / option-pool existence or size.</span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">Precise frequency and scope of investor reporting in the loan contract (beyond statutory accounts and the platform’s investor-relations area).</span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">Full nature of the related-party arrangements with Tytonis Operations GmbH (29.53% shareholder) and Veyx Pharma within the EUR 903,000 subordinated balance.</span></span></li> </ul> <p> </p> <h2><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">📊 Score breakdown</span></span></h2> <table cellspacing="0" class="Table" style="border-collapse:collapse; border:none; width:6.5in"> <thead> <tr> <td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:200px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Category</span></strong></span></span></p> </td> <td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:60px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Score</span></strong></span></span></p> </td> <td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:73px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Weight</span></strong></span></span></p> </td> <td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:291px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Verdict & key reason</span></strong></span></span></p> </td> </tr> </thead> <tbody> <tr> <td style="background-color:white; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:200px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Team & founder track record</span></strong></span></span></p> </td> <td style="background-color:#faeeda; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:60px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">68</span></strong></span></span></p> </td> <td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:73px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">18%</span></span></span></p> </td> <td style="background-color:#faeeda; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:291px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Moderate</span></strong><span style="color:black"> — Experienced nanomaterials chemist as CEO and certified GMP/ISO operations, but a public founders-list discrepancy and key-person concentration.</span></span></span></p> </td> </tr> <tr> <td style="background-color:white; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:200px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Technology & IP</span></strong></span></span></p> </td> <td style="background-color:#faeeda; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:60px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">60</span></strong></span></span></p> </td> <td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:73px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">18%</span></span></span></p> </td> <td style="background-color:#faeeda; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:291px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Moderate</span></strong><span style="color:black"> — Patent grants and 2045 protection are company-stated and unverified; proof-of-concept is animal-model only and pre-clinical.</span></span></span></p> </td> </tr> <tr> <td style="background-color:white; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:200px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Regulatory & clinical pathway</span></strong></span></span></p> </td> <td style="background-color:#faece7; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:60px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">42</span></strong></span></span></p> </td> <td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:73px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">17%</span></span></span></p> </td> <td style="background-color:#faece7; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:291px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Caution</span></strong><span style="color:black"> — Pre-clinical asset; the “~85% complete” figure is toward out-licensing, not approval, and Phase II depends on an unsecured VC round.</span></span></span></p> </td> </tr> <tr> <td style="background-color:white; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:200px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Market & competition</span></strong></span></span></p> </td> <td style="background-color:#faece7; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:60px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">58</span></strong></span></span></p> </td> <td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:73px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">13%</span></span></span></p> </td> <td style="background-color:#faece7; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:291px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Caution</span></strong><span style="color:black"> — Large, validated non-opioid pain market, but Vertex’s FDA-approved Journavx is a well-capitalised competitor in the same indication.</span></span></span></p> </td> </tr> <tr> <td style="background-color:white; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:200px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Business model & traction</span></strong></span></span></p> </td> <td style="background-color:#faece7; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:60px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">55</span></strong></span></span></p> </td> <td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:73px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">14%</span></span></span></p> </td> <td style="background-color:#faece7; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:291px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Caution</span></strong><span style="color:black"> — Real CDMO revenue and grants, but customer counts and EUR 1.2–1.8bn licensing estimates are company-stated, and the two financial sheets conflict.</span></span></span></p> </td> </tr> <tr> <td style="background-color:white; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:200px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Instrument & investor terms</span></strong></span></span></p> </td> <td style="background-color:#fcebeb; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:60px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">30</span></strong></span></span></p> </td> <td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:73px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">20%</span></span></span></p> </td> <td style="background-color:#fcebeb; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:291px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Weak</span></strong><span style="color:black"> — Deeply subordinated loan with pre-insolvency enforcement bar, no fixed return, no voting, and effective illiquidity to 2031.</span></span></span></p> </td> </tr> </tbody> </table> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong>Why these weights? </strong>This is a regulated deeptech drug-development company, so technology/IP and the regulatory/clinical pathway are weighted heavily (18% and 17%) alongside team (18%), reflecting that execution risk in pharma is concentrated in science and approval. Because the instrument is an unusually investor-unfavourable subordinated loan and the reader is a non-professional, instrument & investor terms carries the single largest weight (20%). Market & competition (13%) and business model & traction (14%) round out the 100%. No category was scored N/A, so no weight redistribution was required. Data-quality caps were respected: all MODERATE-quality categories sit below the 85 ceiling, and the instrument category (STRONG data quality, since terms are fully disclosed) scores low on merit, not on data limits.</span></span></p> <h2><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">🔍 Detailed review</span></span></h2> <h3><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">Team & founder track record</span></span></h3> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">The company reports a 12-person specialist team across more than 650 sqm, led by founder/CEO Dr. Sam Dylan Moré (PhD chemist, 20+ years in bio-/nanomaterials, holding 56.39% of equity), with named heads of manufacturing and quality control including an accredited Qualified Person. Operational credentials are concrete: ISO 9001 since 2015, GMP certification in 2022 (LaGeSo), and a completed manufacturing-authorisation inspection in September 2025.</span></span></p> <table cellspacing="0" class="Table" style="border-collapse:collapse; border:none; width:6.5in"> <thead> <tr> <td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:312px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">✅ Strengths</span></strong></span></span></p> </td> <td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:312px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">⚠️ Gaps</span></strong></span></span></p> </td> </tr> </thead> <tbody> <tr> <td style="background-color:white; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:312px"> <ul> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Deep, relevant scientific leadership in nanomaterials and pharmaceutical quality management.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Verified certifications (ISO 9001, GMP) and a completed 2025 manufacturing-authorisation inspection.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Named, credentialed functional leads (manufacturing, QC/Qualified Person).</span></span></span></li> </ul> </td> <td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:312px"> <ul> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Public sources and the project text give different founder lists (five names incl. Emanuel Fleige vs three names plus two post-docs) — an unresolved discrepancy.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Heavy key-person concentration: the CEO holds 56.39% and is the stated driving force.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">No clinical-development or out-licensing track record for a human drug is evidenced in the dossier.</span></span></span></li> </ul> </td> </tr> </tbody> </table> <h3><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">Technology & IP</span></span></h3> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">The platform is a dendritic core-multishell nano-carrier (from Prof. Rainer Haag’s group) positioned as an approved opioid plus a novel carrier, which the company argues enables faster, generic-style approval while retaining patent protection. The company reports platform patents granted in the EU, USA, and Canada, two further patents to be filed in December 2025 for protection to 2045, and exclusive ownership of the regulatory dossier.</span></span></p> <table cellspacing="0" class="Table" style="border-collapse:collapse; border:none; width:6.5in"> <thead> <tr> <td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:312px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">✅ Strengths</span></strong></span></span></p> </td> <td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:312px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">⚠️ Risks</span></strong></span></span></p> </td> </tr> </thead> <tbody> <tr> <td style="background-color:white; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:312px"> <ul> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Differentiated peripheral-delivery mechanism with a plausible regulatory rationale (known active ingredient).</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Company-stated granted patents in three major jurisdictions and a defined IP-extension plan.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Academic pedigree (FU Berlin/Charité/Fraunhofer collaborations).</span></span></span></li> </ul> </td> <td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:312px"> <ul> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Patent grants, the 2045 term, and “worldwide” scope are company-stated; specific patent numbers were not found in public search.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Evidence is proof-of-concept in animal models only — no human data yet.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Limited independent validation of the platform’s clinical efficacy and safety.</span></span></span></li> </ul> </td> </tr> </tbody> </table> <h3><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">Regulatory & clinical pathway</span></span></h3> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">The asset is pre-clinical, with Phase I planned to start Q3 2026 and Phase II in Q3 2027. The company reports the path to Phase II is “clearly defined,” with authority contact established and specialist consultancy support, and states development is “~85% complete” — a figure the dossier flags as completion toward out-licensing, not toward marketing approval.</span></span></p> <table cellspacing="0" class="Table" style="border-collapse:collapse; border:none; width:6.5in"> <thead> <tr> <td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:312px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">✅ Strengths</span></strong></span></span></p> </td> <td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:312px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">⚠️ Gaps</span></strong></span></span></p> </td> </tr> </thead> <tbody> <tr> <td style="background-color:white; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:312px"> <ul> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Defined regulatory roadmap with stated authority engagement and nanomaterials-experienced advisers.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Fraunhofer conducts the preclinical safety studies and Phase I, lending institutional capability.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Generic-style approach may genuinely shorten the approval path versus a new chemical entity.</span></span></span></li> </ul> </td> <td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:312px"> <ul> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Pre-Phase-I means the highest-risk clinical milestones are still ahead.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">The “85% complete” figure measures progress to out-licensing, not approval — easily misread.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Phase II depends on a EUR 3–6m VC round that is not yet secured.</span></span></span></li> </ul> </td> </tr> </tbody> </table> <h3><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">Market & competition</span></span></h3> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">The target market — postoperative and oncological pain, driven by ageing populations and the opioid crisis — is large and well-documented (the dossier cites WHO’s ~600,000 drug-related deaths in 2019, ~80% opioid-related). Public research in the dossier notes Vertex’s Journavx (suzetrigine), the first FDA-approved non-opioid post-surgical analgesic (January 2025), with blockbuster (>$1bn) sales projections, validating demand while signalling serious competition.</span></span></p> <table cellspacing="0" class="Table" style="border-collapse:collapse; border:none; width:6.5in"> <thead> <tr> <td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:312px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">✅ Strengths</span></strong></span></span></p> </td> <td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:312px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">⚠️ Threats</span></strong></span></span></p> </td> </tr> </thead> <tbody> <tr> <td style="background-color:white; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:312px"> <ul> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Large, growing, and politically supported market for non-addictive analgesia.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Recent FDA approval of a non-opioid competitor validates the category’s commercial viability.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Differentiated mechanism (nano-delivered opioid vs sodium-channel inhibition) offers a distinct positioning.</span></span></span></li> </ul> </td> <td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:312px"> <ul> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Vertex is a well-capitalised, already-approved competitor in the same indication.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Customers are future licensees; demand for DendroPharm’s specific asset is unproven.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Market-leadership claims (“among top worldwide”) are company-stated and not independently validated.</span></span></span></li> </ul> </td> </tr> </tbody> </table> <h3><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">Business model & traction</span></span></h3> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">The model has three pillars: NanoOpiate drug development to out-licensing; a veterinary cat-ointment out-licensed in 2021 (approval expected 2026); and CDMO/project services. The company reports ~EUR 600,000 of 2026 customer inquiries, 6 drug-development and 4 nanomaterial-synthesis customers, and ~70–80% public funding of internal research, with annual public funding of roughly EUR 200k–500k.</span></span></p> <table cellspacing="0" class="Table" style="border-collapse:collapse; border:none; width:6.5in"> <thead> <tr> <td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:312px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">✅ Strengths</span></strong></span></span></p> </td> <td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:312px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">⚠️ Gaps</span></strong></span></span></p> </td> </tr> </thead> <tbody> <tr> <td style="background-color:white; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:312px"> <ul> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Diversified near-term revenue (CDMO services plus a veterinary licensing stream) cushions the long drug timeline.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Documented grant funding (BMBF NANOpain EUR 461,926; Pro FIT) supports the burn.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Existing customers and certifications enable paid contract manufacturing.</span></span></span></li> </ul> </td> <td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:312px"> <ul> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Customer counts and the EUR 1.2–1.8bn licensing estimate are company-stated and unverified.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">The Target and Base financial sheets conflict on 2025 ‘actuals’ and on out-licensing magnitude/timing (EUR 45m vs 35m in 2030).</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">High reliance on grants and a 257% debt ratio (per the 31.12.2023 accounts) signal funding fragility.</span></span></span></li> </ul> </td> </tr> </tbody> </table> <h3><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">Instrument & investor terms</span></span></h3> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">The instrument is a profit-participating subordinated loan with a pre-insolvency enforcement bar — fully disclosed in the VIB, which is why data quality is strong even though the terms themselves are unfavourable. The investor receives no equity, no voting rights, no fixed coupon, and deep subordination, with effective illiquidity until 30 April 2031. The return depends entirely on the company’s profit, end-of-term value, or an exit.</span></span></p> <table cellspacing="0" class="Table" style="border-collapse:collapse; border:none; width:6.5in"> <thead> <tr> <td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:312px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">✅ Strengths</span></strong></span></span></p> </td> <td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:312px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">⚠️ Risks</span></strong></span></span></p> </td> </tr> </thead> <tbody> <tr> <td style="background-color:white; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:312px"> <ul> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Terms are transparently and completely disclosed in the statutory VIB.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">No capital-call (Nachschusspflicht) obligation — maximum loss is the amount invested.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Exit-interest clause gives some upside participation if a >50% sale occurs during the term.</span></span></span></li> </ul> </td> <td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:312px"> <ul> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Pre-insolvency enforcement bar can lawfully block interest and repayment before insolvency.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">Deepest-rank subordination — paid only after all other creditors, including §39(1) InsO claims.</span></span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">No fixed return, no voting, and no functioning secondary market until 2031.</span></span></span></li> </ul> </td> </tr> </tbody> </table> <h2><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">🚩 Red flags & integrity checks</span></span></h2> <table cellspacing="0" class="Table" style="border-collapse:collapse; border:none; width:6.5in"> <tbody> <tr> <td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:47px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">1</span></strong></span></span></p> </td> <td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:577px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Missing critical data</span></strong><span style="color:black"> — Valuation methodology for the EUR 10m pre-money, ESOP, founder vesting, and the full nature of the Tytonis/Veyx related-party arrangements are not disclosed.</span></span></span></p> </td> </tr> <tr> <td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:47px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">2</span></strong></span></span></p> </td> <td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:577px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Internal inconsistencies</span></strong><span style="color:black"> — The Target and Base financial sheets disagree on 2025 ‘actual’ figures and on out-licensing magnitude/timing (EUR 45m vs 35m in 2030; EUR 15m vs 10m in 2031), with no reconciliation.</span></span></span></p> </td> </tr> <tr> <td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:47px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">3</span></strong></span></span></p> </td> <td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:577px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">External discrepancies</span></strong><span style="color:black"> — Public ‘founded by’ lists (five names incl. Emanuel Fleige) differ from the project text’s founder narrative (three names plus two post-docs).</span></span></span></p> </td> </tr> <tr> <td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:47px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">4</span></strong></span></span></p> </td> <td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:577px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Negative public information</span></strong><span style="color:black"> — <em>None found in public registries or news searches.</em></span></span></span></p> </td> </tr> <tr> <td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:47px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">5</span></strong></span></span></p> </td> <td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:577px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Prior fundraises</span></strong><span style="color:black"> — A 2013 ProFIT first round of ~EUR 1.2m and prior FunderNation crowd-financing inflows appear in the dossier (EUR 530k/653k lines in 2024–25); precise prior-campaign amounts/valuation and whether milestones were met are not fully verified.</span></span></span></p> </td> </tr> <tr> <td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:47px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">6</span></strong></span></span></p> </td> <td style="background-color:white; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:577px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">Valuation reasonableness</span></strong><span style="color:black"> — The EUR 10m pre-money is issuer-set with no disclosed methodology and no third-party benchmark; for a pre-Phase-I asset it is entirely forward-looking on out-licensing potential and cannot be independently corroborated from the dossier.</span></span></span></p> </td> </tr> </tbody> </table> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">📝 Data quality notes</span></span></p> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong>Categories scored N/A: </strong>None.</span></span></p> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong>Categories with LIMITED data quality: </strong>None — all evaluated categories had MODERATE or STRONG data quality in the dossier.</span></span></p> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong>Most material missing items that would change the evaluation if obtained:</strong></span></span></p> <ul> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">Independent verification of the patent grants, scope, and 2045 term (currently company-stated).</span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">A reconciliation of the conflicting Target and Base financial scenarios, especially the 2025 ‘actuals’ and out-licensing assumptions.</span></span></li> <li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">Confirmation that the EUR 3–6m Phase II VC round is secured, and the valuation methodology behind the EUR 10m pre-money.</span></span></li> </ul> <table cellspacing="0" class="Table" style="border-collapse:collapse; border:none; width:6.5in"> <tbody> <tr> <td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:624px"> <p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><em><span style="color:black">Memo generated by AI from public information and platform-disclosed company materials. Investors must perform their own due diligence. Past fundraising or operational performance does not guarantee future results. Crowdfunding investments are illiquid, high-risk, and capital loss is possible.</span></em></span></span></p> </td> </tr> </tbody> </table> <p> </p>
See full overview
Ask question
Ask AI about this project
Beta
Start a conversation
Send a message to begin chatting with the AI assistant
Like this project?
Platform offering this project
FunderNation DE
Risk Level
High
Return Level
High
Return Level
High
Min. Investment
EUR 100
Total Funded
EUR 80.0M
